Patients with factors that increase the risk of bleeding who were dosereduced to lixiana

EFFICACY AND SAFETY IN PATIENTS WITH FACTORS THAT INCREASE THE RISK OF BLEEDING WHO WERE DOSE-REDUCED TO LIXIANA^® (edoxaban) 30 mg

Once-daily LIXIANA^® (edoxaban) demonstrated similar risk reduction in efficacy vs well-managed warfarin in NVAF patients with factors that increase the risk of bleeding who were dose-reduced to LIXIANA^® 30 mg qd.¹

STROKE/SEE EVENTS (PRIMARY EFFICACY ENDPOINT) IN PATIENTS DOSE-REDUCED AT RANDOMIZATION²

Once-daily LIXIANA^® demonstrated consistent efficacy results across a broad range of NVAF patients³

STROKE/SEE EVENTS (PRIMARY EFFICACY ENDPONT) ACROSS MAJOR SUBPOPULATIONS (INTENTION-TO-TREAT POPULATION)¹

a Includes patients taking LIXIANA^® 60 mg and those dose-reduced to 30 mg.
b Congestive heart failure
c Transient ischemic attack
d Myocardial infarction

Once-daily LIXIANA^® (edoxaban) demonstrated consistently favorable safety vs well-managed warfarin in NVAF patients with factors that increase the risk of bleeding who were dose-reduced to LIXIANA^® 30 mg qd.¹

MAJOR BLEEDING EVENTS (PRIMARY SAFETY ENDPOINT) IN PATIENTS DOSE-REDUCED AT RANDOMIZATION²

a Relative risk reduction.

Once-daily LIXIANA^® demonstrated consistent safety results across a broad range of NVAF patients.³

MAJOR BLEEDING EVENTS (PRIMARY SAFETY ENDPOINT) ACROSS MAJOR SUBPOPULATIONS (ON-TREATMENT POPULATION)¹

a Includes patients taking LIXIANA^® 60 mg and those dose-reduced to 30 mg

References:

Back to
previous page

Daiichi Sankyo Europe GmbH (“Daiichi Sankyo”) maintains such parts of this site that are expressly directed to an international audience except the UK, USA and Japan for information, education, and communication. While you are free to browse the site, your access to and use of the site is subject to the following terms and conditions (“Terms and Conditions”) and all applicable laws. By accessing and browsing the site, you accept, without limitation or qualification, the Terms and Conditions.

TERMS AND CONDITIONS

The content of this site is NOT INTENDED TO PROVIDE MEDICAL ADVICE, nor meant to be a substitute for advice provided by a physician or other qualified healthcare professional. The information on this site should not be relied on in providing medical advice.

Copyrights and Trademarks

All content of this website, such as text, publications, newsletters, articles, opinions, minutes, notices, views, graphics, images, HTML code, multimedia clips, Java code, and the selection and arrangement of information ("materials") is protected by copyright and other intellectual property laws. All images and text are owned by or licenced to Daiichi Sankyo and, except as provided within these Terms and Conditions, may not be downloaded, distributed, stored, reused, reposted, modified, or otherwise used without the express written permission of Daiichi Sankyo. Daiichi Sankyo neither warrants nor represents that your use of material displayed on the site will not infringe rights of third parties.

Non-commercial Use

You may print a single copy of the content for your own personal, non-commercial use, provided you also retain all copyright and other proprietary notices contained in the materials or as specified on the site. Except for the images expressly stated to be “Downloadable” on the site (“Expressly Downloadable Images”), the further use, re-use, copying, distribution, redistribution, modification, publication, or re-posting of or to any part of this site (including the text, images, audio, and video) is strictly prohibited and nothing contained on this site should be construed as granting, by implication, estoppel, or otherwise, any licence or right to use any Daiichi Sankyo intellectual property right (including, but not limited to any patent, trademark, trade name, copyright or trade secret). The Expressly Downloadable Images may be used for non-commercial use, provided you also retain all copyright notices.

No offer and No solicitation

No information provided on this website constitutes an offer of solicitation for the purchase or disposal of, trading or any transaction in any Daiichi Sankyo securities or products. Investors must not rely on this information for investment decisions.

The website is neither directed at nor designed for use by children (i.e., anyone under 13 years old). To best protect the privacy of children, we ignore any data collected from a user known to be under 13 years old without the proper permission of his or her legal guardian. If requested, a child’s guardian can view any information provided by the child and have it deleted. While Daiichi Sankyo uses reasonable care to ensure that information is accurate at the time it is added on this site, the contents of this site are provided to you "as is," without warranty of any kind, either expressed or implied, including, but not limited to the implied warranties of merchantability, fitness for a particular purpose, or non-infringement and Daiichi Sankyo makes no representations as to the availability, accuracy, or completeness of the content of this site. Daiichi Sankyo may make changes to these materials at any time, without notice, and makes no commitment to update the information contained herein. Therefore, information which has been accurate when first published may no longer be up to date. Daiichi Sankyo shall not be liable for any damages or injury resulting from your access to, or inability to access, this site or from your reliance on any information at this site, or for any viruses that may infect your computer equipment or other property on account of your access to, use of, or browsing in this site or your downloading of any materials, data, text, images, video or audio from this site.

Links to Other Sites

Our site may provide links or references to other Websites not affiliated with Daiichi Sankyo, as well as e-mail links that were checked prior their inclusion. Daiichi Sankyo is not responsible for the content of such other sites and shall not be liable for any damages or injury arising from your access to such sites. Links to other sites are provided only as a convenience to users of our site. A link does not constitute an affiliation with any site or organisation. A link does not constitute an endorsement by any organisation, or an endorsement of any organisation. Should we learn that such third-party websites contain illegal content, we will immediately remove such links.

Feedback and Suggestions

Daiichi Sankyo welcomes your feedback and suggestions about how to improve this site. Any ideas, suggestions, information, know-how, material, or other content (collectively, "content") received through this site, however, will be deemed to include a royalty-free, perpetual, irrevocable, transferable, worldwide, nonexclusive right and licence for Daiichi Sankyo to adopt, publish, reproduce, disseminate, transmit, distribute, copy, use, modify, create derivative works, display (in whole or part), or act on such content without additional approval or consideration, in any form, media, or technology now known or later developed for the full term of any rights that may exist in such content.

NonvalvularAtrial Fibrillation (NVAF)Clinical Trial

EFFICACY AND SAFETY IN PATIENTS WITH FACTORS THAT INCREASE THE RISK OF BLEEDING WHO WERE DOSE-REDUCED TO LIXIANA® (edoxaban) 30 mg

STROKE/SEE EVENTS (PRIMARY EFFICACY ENDPOINT) IN PATIENTS DOSE-REDUCED AT RANDOMIZATION2

STROKE/SEE EVENTS (PRIMARY EFFICACY ENDPONT) ACROSS MAJOR SUBPOPULATIONS (INTENTION-TO-TREAT POPULATION)1

MAJOR BLEEDING EVENTS (PRIMARY SAFETY ENDPOINT) IN PATIENTS DOSE-REDUCED AT RANDOMIZATION2

MAJOR BLEEDING EVENTS (PRIMARY SAFETY ENDPOINT) ACROSS MAJOR SUBPOPULATIONS (ON-TREATMENT POPULATION)1

TERMS OF USE